Preoperative and adjuvant therapies for upper gastrointestinal cancers

Expert Review of Anticancer Therapy

Volumn 5, Issue 4, 2005, Pages 719-725

  Varadhachary, Gauri ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Gastrointestinal cancer; Preoperative therapy

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CELECOXIB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DRUG DOSE REGIMEN; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL RADIOGRAPHY; GASTROINTESTINAL SURGERY; HIGH RISK PATIENT; HUMAN; LAPAROSCOPY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE CARE; REVIEW; RISK ASSESSMENT; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; UPPER GASTROINTESTINAL TRACT;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; SURVIVAL;

EID: 24044461722     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.4.719     Document Type: Review

References (32)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Bedenne L, Bouche O, Triboulet J-P et al. Randomized Phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc. Am. Soc. Clin. Oncol. (Conference) (2002).
3. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J. Clin. Oncol. 23, 2310-2317 (2005)
4. al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J. Clin. Oncol. 15, 277-284 (1997)
5. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J. Clin. Oncol. 20, 1167-1174 (2002).
6. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 339, 1979-1984 (1998).
7. Group. MRCOCW: surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359, 1727-1233 (2002).
8. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N. Engl. J. Med. 337, 161-167 (1997).
9. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335, 462-467 (1996).
10. Urba SG, Orringer MB, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 19, 305-313 (2001).
11. Urba S. Esophageal cancer: preoperative or definitive chemoradiation. Ann. Oncol. 15(Suppl. 4), 93-96 (2004).
12. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 185, 538-543 (2003).
13. Rice DC, Correa AM, Vaporciyan AA et al. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann. Thorac. Surg. 79, 391-397 (2005).
14. Govindan R, McLeod H, Mantravadi P et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Huntingt) 18, 18-21 (2004).
15. Cunningham D, Allum W, Stenning S et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Abstract No: 4001, ASCO (2005).
16. Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J. Clin. Oncol. 22, 2774-2780 (2004).
17. Ajani JA, Mansfield PF, Crane CH et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J. Clin. Oncol. 23, 1237-1244 (2005).
18. Macdonald JS, Fleming TR, Peterson RF et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann. Surg. Oncol. 2, 488-494 (1995).
19. Lise M, Nitti D, Marcher A et al. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann. Surg. Oncol. 2, 495-501 (1995).
20. Coombes RC, Schein PS, Chilvers CE et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J. Clin. Oncol. 8, 1362-1369 (1990).
21. Bouche O, Ychou M, Burtin P et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized Phase III trial (8801). Ann. Oncol. (2005).
22. Chipponi J, Huguier M, Pezet D et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am. J. Surg. 187, 440-445 (2004).
23. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur. J. Surg. 168, 597-608 (2002).
24. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer 35, 1059-1064 (1999).
25. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11, 1441-1447 (1993).
26. Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol. 11, 837-843 (2000).
27. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88, 21-27 (2002).
28. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001).
29. Hundahl SA, Macdonald JS, Benedetti J et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann. Surg. Oncol. 9, 278-286 (2002).
30. Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 11, 3778-3783 (2005).
31. Tajima Y, Shimoda T, Nakanishi Y et al. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil. J. Cancer Res. Clin. Oncol. 129, 683-690 (2003).
32. Grau JJ, Domingo-Domenech J, Morente V et al. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology 66, 226-233 (2004).